Inhibition of bone resorption by bisphosphonates: interactions between bisphosphonates, osteoclasts, and bone.
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Bisphosphonates are nonbiodegradable pyrophosphate analogues that are being used increasingly to inhibit bone resorption in disorders characterized by excessive bone loss. We have previously found that dichloromethylene bisphosphonate (Cl2MBP) inhibits bone resorption through injury to the cells that resorb Cl2MBP-contaminated surfaces. 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (AHPrBP) is a more potent inhibitor of bone resorption in vivo, and we have attempted to identify a step in the resorptive pathway that accounts for this increased potency. We found that when osteoclasts, isolated from neonatal rat long bones, were incubated on bone slices in the presence of bisphosphonates, AHPrBP was less, rather than more potent as a resorption-inhibitor than Cl2MBP. The greater sensitivity of resorption to AHPrBP in vivo could neither be attributed to an effect of AHPrBP on the ability of osteoblastic cells to stimulate resorption in response to calcium-regulating hormones in vitro nor to an effect on osteoclast generation: osteoclast formation was unaffected by concentrations of AHPrBP 10-fold higher than those of Cl2MBP which inhibit bone resorption in the bone slice assay. We also found no evidence for impaired osteoclast generation in vivo in AHPrBP-treated rats. These results suggest that the comparisons of potency in vitro do not include all the factors responsible for determining bisphosphonate potency in vivo. Because bisphosphonates owe the specificity of their actio…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This phenomenon is consistent with previous observations that bisphosphonates suppress bone resorption via injury to osteoclasts when they solubilize bisphosphonate-contaminated bone (139, 140).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [139]
Citations
Cites
Calcitonin alters behaviour of isolated osteoclasts
Chambers, T. J., & Magnus, C. J. (1982) · The Journal of Pathology · doi:10.1002/path.1711360104 · Cited by 504 · cited 1×
“Osteoclasts were isolated from neonatal rat long bones as previously described [28].”
MethodSelf-citationSchenk, R., Merz, W. A., Mühlbauer, R., Russell, R. G. G., & Fleisch, H. (1973) · Calcified Tissue Research · doi:10.1007/bf02547219 · Cited by 482
Osteoblastic Cells Mediate Osteoclastic Responsiveness to Parathyroid Hormone*
McSHEEHY, P. M. J., & CHAMBERS, T. J. (1986) · Endocrinology · doi:10.1210/endo-118-2-824 · Cited by 407 · cited 3×
“The number of resorption pits and the plan area of bone resorption were assessed as previously described [29].”
BackgroundMethodSelf-citationThe binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals
Jung, A., Bisaz, S., & Fleisch, H. (1973) · Calcified Tissue Research · doi:10.1007/bf02547227 · Cited by 381 · cited 1×
“Bisphosphonates (PCPs) are nonbiodegradable analogues of pyrophosphate with a high binding affinity for hydroxyapatite crystals [1].”
BackgroundHughes, D. E., MacDonald, B. R., Russell, R. G., & Gowen, M. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114100 · Cited by 357 · cited 2×
“Other experimental models that test the function of mature osteoclasts have similarly failed to demonstrate increased potency for AHPrBP, and this has led to the suggestion that AHPrBP impairs osteoclast generation [25].”
BackgroundTwo modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix.
Boonekamp, P. M., van der Wee-Pals, L. J. A., LENNEP, M. V., Cw, T., & Bijvoet, O. L. (1986) · PubMed · Cited by 345
Reid, I. R., Alexander, C. J., King, A. R., & Ibbertson, H. K. (1988) · The Lancet · doi:10.1016/s0140-6736(88)92721-3 · Cited by 341
(1985) · De Gruyter eBooks · doi:10.1515/9783112330005 · Cited by 325
Carano, A., Teitelbaum, S. L., Konsek, J. D., Schlesinger, P. H., & Blair, H. C. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114459 · Cited by 314 · cited 1×
“[38] who, using chick osteoclasts, found that AHPrBP was more potent than C12MBP by an order of magnitude.”
Structure-activity relationships of various bisphosphonates
Shinoda, H., Adamek, G., Felix, R., Fleisch, H., Schenk, R., & Hagan, P. (1983) · Calcified Tissue International · doi:10.1007/bf02405012 · Cited by 306 · cited 2×
“The relative potency of 3-amino-l-hydroxypropyl idene- l , l -b isphosphonate (AHPrBP, formerly APD), as judged by inhibition of bone resorption in organ culture, does not correlate with the increased relative potency of AHPrBP in vivo [16].”
BackgroundTREATMENT OF PAGET'S DISEASE WITH (3-AMINO-1-HYDROXYPROPYLIDENE)-1, 1-BISPHOSPHONATE (A.P.D.)
Frijlink, W. B., Bijvoet, O. M., Te Velde, J., & Heynen, G. (1979) · The Lancet · doi:10.1016/s0140-6736(79)91318-7 · Cited by 258 · cited 1×
“Administration of PCPs to experimental animals rapidly curtails bone resorption [2--4] and it is for this reason that they have become established as therapeutic agents in clinical disorders characterized by increased bone degradation, including Paget 's disease of bone [5-8], and hypercalcemia of malignancy [6, 9, 10…”
BackgroundAltman, R. D., Johnston, C. C., Khairi, M. R. A., Wellman, H., Serafini, A. N., & Sankey, R. R. (1973) · New England Journal of Medicine · doi:10.1056/nejm197312272892601 · Cited by 248 · cited 1×
“Administration of PCPs to experimental animals rapidly curtails bone resorption [2--4] and it is for this reason that they have become established as therapeutic agents in clinical disorders characterized by increased bone degradation, including Paget 's disease of bone [5-8], and hypercalcemia of malignancy [6, 9, 10…”
BackgroundCOMPARISON OF THREE INTRAVENOUS BISPHOSPHONATES IN CANCER-ASSOCIATED HYPERCALCAEMIA
Ralston, S., Patel, U., Fraser, W., Gallacher, S., Dryburgh, F., Cowan, R., & Boyle, I. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91791-1 · Cited by 195
Flanagan, A. M., & Chambers, T. J. (1989) · Bone and Mineral · doi:10.1016/0169-6009(89)90021-4 · Cited by 195 · cited 7×
“This reduction was accompanied by degenerative morphological changes similar to those previously observed using CIzMBP [17].”
BackgroundResultSelf-citationRalston, S. H., Dryburgh, F. J., Cowan, R. A., Gardner, M. D., Jenkins, A. S., & Boyle, I. T. (1985) · The Lancet · doi:10.1016/s0140-6736(85)90848-7 · Cited by 192
Dr. Löwik, C. W. G. M., Van Der Pluijm, G., Van Der Wee-Pals, L. J. A., Van Treslong-De Groot, H. B., & Bijvoet, O. L. M. (1988) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650030210 · Cited by 191
PREVENTION OF POSTMENOPAUSAL BONE LOSS BY TILUDRONATE
REGINSTER, J. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92927-9 · Cited by 178
Douglas, D., Graham G, R., Preston, C., Prenton, M., Duckworth, T., Kanis, J., Eric Preston, F., & Stuart Woodhead, J. (1980) · The Lancet · doi:10.1016/s0140-6736(80)91496-8 · Cited by 177 · cited 1×
“Administration of PCPs to experimental animals rapidly curtails bone resorption [2--4] and it is for this reason that they have become established as therapeutic agents in clinical disorders characterized by increased bone degradation, including Paget 's disease of bone [5-8], and hypercalcemia of malignancy [6, 9, 10…”
BackgroundReitsma, P. H., Bijvoet, O. L. M., Verlinden-Ooms, H., & van der Wee-Pals, L. J. A. (1980) · Calcified Tissue International · doi:10.1007/bf02408534 · Cited by 161
Effect of substrate composition on bone resorption by rabbit osteoclasts
Chambers, T. J., Thomson, B. M., & Fuller, K. (1984) · Journal of Cell Science · doi:10.1242/jcs.70.1.61 · Cited by 141
Self-citationSleeboom, H., van Oosterom, A. T., Bijvoet, O. L. M., GLEED, J. H., & O'Riordan, J. H. (1983) · The Lancet · doi:10.1016/s0140-6736(83)90231-3 · Cited by 138 · cited 1×
“Administration of PCPs to experimental animals rapidly curtails bone resorption [2--4] and it is for this reason that they have become established as therapeutic agents in clinical disorders characterized by increased bone degradation, including Paget's disease of bone [5-8], and hypercalcemia of malignancy [6, 9, 10…”
BackgroundFleisch, H. A., Maerki, J., & Russell, R. G. G. (1966) · Experimental Biology and Medicine · doi:10.3181/00379727-122-31123 · Cited by 121 · cited 1×
“It was originally thought that they might act through physicochemical inhibition of hydroxyapatite crystal dissolution [14, 15], but no correlation has been found between the ability of PCPs to inhibit bone resorption in vitro or in vivo and their ability to inhibit hydroxyapati te dissolution [16].”
BackgroundHATTERSLEY, G., & CHAMBERS, T. J. (1989) · Endocrinology · doi:10.1210/endo-124-4-1689 · Cited by 121 · cited 1×
“However, in these experiments the criteria used to identify osteoclast differentiation were morphological, rather than functional; morphology is not a reliable guide to osteoclast differentiation in vitro [37].”
BackgroundSelf-citationClodronate kinetics and bioavailability
Yakatan, G. J., Poynor, W. J., Talbert, R. L., Floyd, B. F., Slough, C. L., Ampulski, R. S., & Benedict, J. J. (1982) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1982.51 · Cited by 117 · cited 1×
“The available evidence suggests that a 6-8 times greater proportion of an intravenous dose of AHPrBP remains unexcreted after 24 hours, most of which is bound to bone, compared with C12MBP [40, 41].”
BackgroundThe effect of several diphosphonates on acid phosphohydrolases and other lysosomal enzymes
Felix, R., Graham, R., Russell, R. G. G., & Fleisch, H. A. (1976) · Biochimica et Biophysica Acta (BBA) - Enzymology · doi:10.1016/0005-2744(76)90291-6 · Cited by 93 · cited 1×
“PCPs interfere with many aspects of the intermediary metabolism of ceils [19-23], and the above observations suggest that CI2MBP acts as a toxic compound with a high affinity for bone, which inhibits bone resorption through injury to the ceils that solubilize Cl2MBP-contaminated surfaces.”
BackgroundTOBIAS, J., & CHAMBERS, T. J. (1989) · Endocrinology · doi:10.1210/endo-125-3-1290 · Cited by 90 · cited 1×
“The depth of each pit was calculated as the distance through which the objective, focused on the surface of the bone slice, had to be moved to become focused on the base of the excavation under observation, as previously described [30].”
MethodSelf-citationMiller, S. C., & Jee, W. S. S. (1977) · Calcified Tissue International · doi:10.1007/bf02012787 · Cited by 82
Bisphosphonates : Mechanisms of Action and Clinical Applications
Fleisch, H. A. (1983) · Medical Entomology and Zoology · Cited by 76
The alteration of osteoclast morphology by diphosphonates in bone organ culture
Rowe, D. J., & Hausmann, E. (1976) · Calcified Tissue International · doi:10.1007/bf02546397 · Cited by 74 · cited 1×
“For dichloromethylene bisphosphonate (C12MBP, formerly C12MDP), inhibition of bone resorption is associated with morphological evidence of degenerative changes in osteoclasts, the cells that resorb bone, without morphological effect on cells other than osteoclasts [17, 18].”
BackgroundGuenther, H. L., Guenther, H. E., & Fleisch, H. A. (1981) · Biochemical Journal · doi:10.1042/bj1960293 · Cited by 63 · cited 1×
“PCPs interfere with many aspects of the intermediary metabolism of ceils [19-23], and the above observations suggest that CI2MBP acts as a toxic compound with a high affinity for bone, which inhibits bone resorption through injury to the ceils that solubilize Cl2MBP-contaminated surfaces.”
BackgroundReid, I., Alexander, C., King, A., & Ibbertson, H. K. (1988) · Maturitas · doi:10.1016/0378-5122(88)90035-7 · Cited by 49 · cited 1×
“Administration of PCPs to experimental animals rapidly curtails bone resorption [2--4] and it is for this reason that they have become established as therapeutic agents in clinical disorders characterized by increased bone degradation, including Paget 's disease of bone [5-8], and hypercalcemia of malignancy [6, 9, 10…”
Body, J. J., Magritte, A., Seraj, F., Sculier, J., & Borkowski, A. J. (1989) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650040617 · Cited by 48 · cited 1×
“weight for 4 days) compares with the range that reduces bone resorpt ion in vivo within 1 week [9, 31, 32].”
BackgroundPaget's disease of bone treated in five days with AHPrBP (APD) per Os
Thiébaud, D., Jaeger, P., & Burckhardt, P. (1987) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650020108 · Cited by 34 · cited 1×
“weight for 4 days) compares with the range that reduces bone resorpt ion in vivo within 1 week [9, 31, 32].”
BackgroundDistribution of [14C]clodronate (dichloromethylene bisphosphonate) disodium in mice
Ylitalo, P., Elo, H. A., & Airaksinen, M. M. (1987) · Toxicology and Applied Pharmacology · doi:10.1016/0041-008x(87)90050-0 · Cited by 33
de Vernejoul, M. C., Pointillart, A., Bergot, C., Bielakoff, J., Morieux, C., Laval-Jeantet, A. M., & Miravet, L. (1987) · Calcified Tissue International · doi:10.1007/bf02555701 · Cited by 30
Effect of diphosphonates on glycogen content of rabbit ear cartilage cells in culture
Felix, R., Fast, D. K., Sallis, J. D., & Fleisch, H. A. (1980) · Calcified Tissue International · doi:10.1007/bf02408621 · Cited by 25 · cited 1×
“PCPs interfere with many aspects of the intermediary metabolism of ceils [19-23], and the above observations suggest that CI2MBP acts as a toxic compound with a high affinity for bone, which inhibits bone resorption through injury to the ceils that solubilize Cl2MBP-contaminated surfaces.”
BackgroundMarie, P. J., Hott, M., & Garba, M.-T. (1985) · Calcified Tissue International · doi:10.1007/bf02554873 · Cited by 19
A comparison of the pharmacokinetics of 14C-labelled APD and 99mTc-labelled APD in the mouse
Daley‐Yates, P. T., & Bennett, R. (1988) · Calcified Tissue International · doi:10.1007/bf02555158 · Cited by 15 · cited 1×
“The available evidence suggests that a 6-8 times greater proportion of an intravenous dose of AHPrBP remains unexcreted after 24 hours, most of which is bound to bone, compared with C12MBP [40, 41].”
BackgroundDiphosphonates and polyphosphates in medicine
Russell, R. G. G. (1975) · British Journal of Hospital Medicine · Cited by 11
Research works printed but not linked: 3
- Huaux JP, Devogelaer JP, Brasseu JP, Nagant de Deuxchaisnes C (1985) Effect of the diphosphonate APD on dual photon absorptiometry in involutional osteoporosis. In: Norman AW (ed) Vitamin D. A chemical, biochemical and clinical update. Walter de Gruyter, Berlin, pp 998–999
- Ende JJ (1978) Some effects of EHDP and Cl2MDP on the metabolism of isolated bone cells. Proc Kon Med Akad Wet C81:252–264
- Ende JJ, van Rooijen HJM (1979) Some effects of EHDP and Cl2MBP on enzyme activiyt and substrate utilisation by mouse calvaria in tissue culture. Proc Kon Med Akad Wet C. 82:55–63
Cited by
Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo
Hughes, D. E., Wright, K. R., Uy, H. L., Sasaki, A., Yoneda, T., Roodman, D. G., Mundy, G. R., & Dr. Boyce, B. F. (1995) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650101008 · Cited by 1,040
Biochemical markers and skeletal metastases
Demers, L. M., Costa, L., & Lipton, A. (2000) · Cancer · doi:10.1002/1097-0142(20000615)88:12+<2919::aid-cncr7>3.0.co;2-z · Cited by 161
Cellular and molecular mechanisms of action of bisphosphonates
Rogers, M. J., Gordon, S., Benford, H. L., Coxon, F. P., Luckman, S. P., Monkkonen, J., & Frith, J. C. (2000) · Cancer · doi:10.1002/1097-0142(20000615)88:12+<2961::aid-cncr12>3.0.co;2-l · Cited by 977
Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
Hortobagyi, G. N., Theriault, R. L., Lipton, A., Porter, L., Blayney, D., Sinoff, C., Wheeler, H., Simeone, J. F., Seaman, J. J., Knight, R. D., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.6.2038 · Cited by 631
Metadata
- Authors
- Flanagan, A. M., & Chambers, T. J.
- Affiliations
- St George's Hospital (GB)
- St George's, University of London (GB)
- Venue
- Calcified Tissue International
- Published
- 1991-11
- Volume
- 49
- Issue
- 6
- Pages
- 407-415
- ISSN
- 0171-967X (ISSN-L)
- 1432-0827
- OpenAlex
- W2004135633
- Cited by
- 171
- References
- 39
- Citations by year
- 2025: 2 · 2024: 6 · 2023: 6 · 2022: 1 · 2021: 2 · 2020: 1 · 2019: 1 · 2018: 3 · 2017: 3 · 2016: 1 · 2015: 4 · 2014: 5 · 2013: 4 · 2012: 2
- FWCI
- 1.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Calcified Tissue International (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Keywords
- bisphosphonates, bone resorption inhibition, osteoclasts, pyrophosphate analogues, calcitonin, osteoblasts
- MeSH terms
- Pamidronate, Animals, Bone and Bones, Bone Marrow Cells, Bone Resorption, Calcitonin, Cells, Cultured, Clodronic Acid, Diphosphonates, Microscopy, Electron, Osteoclasts, Rats, Inbred Strains, Culture Techniques, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.